Brooklyn Investment Group Purchases 13,013 Shares of GSK PLC Sponsored ADR $GSK

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Brooklyn Investment Group lifted its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 2,126.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,625 shares of the pharmaceutical company's stock after acquiring an additional 13,013 shares during the period. Brooklyn Investment Group's holdings in GSK were worth $528,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. HHM Wealth Advisors LLC boosted its holdings in GSK by 222.2% in the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after purchasing an additional 460 shares during the period. Costello Asset Management INC purchased a new position in GSK in the 1st quarter worth about $31,000. Richardson Financial Services Inc. grew its stake in GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after acquiring an additional 472 shares in the last quarter. Olde Wealth Management LLC purchased a new position in GSK during the 1st quarter valued at about $36,000. Finally, Cary Street Partners Investment Advisory LLC lifted its holdings in shares of GSK by 525.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock valued at $39,000 after buying an additional 852 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Hsbc Global Res upgraded GSK to a "strong sell" rating in a report on Monday, April 28th. Berenberg Bank reiterated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Wall Street Zen upgraded GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Seven research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus target price of $37.38.

GSK Price Performance

GSK traded up $0.0650 on Friday, reaching $40.1450. The stock had a trading volume of 3,403,643 shares, compared to its average volume of 3,847,922. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $44.67. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $81.77 billion, a price-to-earnings ratio of 18.59, a price-to-earnings-growth ratio of 1.74 and a beta of 0.51. The firm has a 50-day moving average of $38.34 and a 200-day moving average of $38.13.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same quarter last year, the firm posted $0.43 earnings per share. The firm's revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a yield of 4.2%. GSK's payout ratio is 77.78%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.